SS Innovations International Inc. (NASDAQ: SSII) has reported record second-quarter revenue, underscoring the accelerating adoption of its SSi Mantra surgical robotic platform. The company posted Q2 2026 revenue of $13.9 million, a 39.4% increase from $10.0 million in the same period last year. Gross profit rose 20.0% to $7.1 million, though gross margin contracted to 50.9% from 59.1% in the year-ago quarter (https://nnw.fm/zxrT1).
For the first half of 2026, revenue reached $25.0 million, up 65.6% from $15.1 million in the prior-year period. Gross profit increased 77.5% to $12.4 million, with an improved gross margin. The company installed 30 SSi Mantra systems during the quarter, a 30.4% increase from the prior year, bringing the total installed base to 224 systems across 12 countries. Cumulative surgeries performed on the platform reached 12,272, reflecting growing clinical acceptance and usage.
The strong financial performance is driven primarily by system sales, with installations serving as the key commercial growth driver. However, the company is also advancing its telesurgery capabilities, which expand the platform's clinical profile and differentiate it in the competitive robotic surgery market.
Looking ahead, regulatory milestones in major markets represent significant catalysts. SS Innovations is targeting FDA clearance for the SSi Mantra by the first quarter of 2027 and EU CE marking by the end of 2026. Achieving these approvals would open access to the U.S. and European markets, likely accelerating adoption and revenue growth. The company's telesurgery achievements further enhance its value proposition, potentially positioning SSi Mantra as a versatile tool for remote and minimally invasive procedures.
The record revenue and expanding installed base underscore strong demand for the SSi Mantra platform. As the company progresses toward regulatory approvals, its growth trajectory appears poised to continue, making it a notable player in the surgical robotics sector. Investors and industry observers will be watching closely for updates on regulatory timelines and further commercial expansion.
